{"entity":{"id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","aka":[],"tldr":"Immunotherapy is given as one flat dose regardless of body size, which means smaller patients get more than they need. Dosing by weight would save a fifth of the drug at no cost to patients.","summary":"Pembrolizumab and nivolumab were developed with weight-based dosing but labelled at flat doses (200 mg, 240 or 480 mg) that exceed the weight-based equivalent for most patients; pharmacokinetic modelling and several observational studies suggest no loss of efficacy from weight-based or capped dosing, and Dutch and other groups estimate savings of 20-30%. The proposal is a regulator-endorsed label update permitting weight-based dosing with dose banding and multi-dose vial sharing, supported by a pragmatic non-inferiority trial where regulators require one.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017)","url":"https://doi.org/10.1038/nrclinonc.2017.31"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-dose-optimisation"],"keyPapers":["paper-checkmate-017-nejm-2015","paper-keynote-189-nejm-2018","paper-keynote-564-nejm-2021","paper-prasad-nat-rev-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Weight-based, banded dosing reduces checkpoint inhibitor drug spend per patient by at least 20% with overall survival non-inferior to flat dosing (hazard ratio upper bound below 1.1).","rationale":"Exposure-response for PD-1 antibodies is flat across the approved range, so the flat doses were chosen for convenience and, arguably, revenue; the drug is the same either way.","test":"Pragmatic registry-based randomised trial in one health system comparing weight-based banded dosing with flat dosing across indications, with survival and cost endpoints; petition regulators for label change on the result.","maturity":"early-clinical","actor":"clinic","cost":"medium","horizonYears":3},"route":"/ideas/idea-reg-weight-based-io-dosing-label/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/"}],"paper":[{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/"},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/"},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/"},{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/"}]}}